Background Thrombotic complications are considered among the main extrapulmonary
manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of …

Background: Numerous tools, including nutritional and inflammatory markers, have been
evaluated as the predictors of poor outcomes in COVID-19 patients. This study aims to verify …

Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …

Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …

Coagulation disorders, endotheliopathy and inflammation are the most common hallmarks
in SARS-CoV-2 infection, largely determining COVID-19's outcome and severity …

Background High incidence of asymptomatic venous thromboembolism (VTE) has been
observed in severe COVID‐19 patients, but the characteristics of symptomatic VTE in …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

A high incidence of thrombosis in hospitalised patients with COVID-19 was identified early
during the pandemic. Accurately quantifying thrombotic risk may assist prognosis and guide …

The COVID-19 pandemic has introduced a global public health threat unparalleled in our
history. The most severe cases are marked by ARDS attributed to microvascular thrombosis …

Background Severe acute respiratory syndrome coronavirus 2 infection may be associated
with a prothrombotic state, predisposing patients for a progressive disease course. We …